UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercially Supplied Sunitinib in Patients with Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma

Participants in this research study have advanced or metastatic kidney cancer and will receive either subitinib or cabozantinib. The purpose of this research study is to find out what effects these drugs have on advanced or metastatic kidney cancer. Sunitinib has been approved by the U.S. Food and Drug Administration (FDA) and cabozantinib is an investigational drug (which means it has not been approved by the FDA). Both medications target special proteins that are on the surface of the kidney cancer cell and both drugs are taken by mouth.

Approximately 15 people will take part in this study at the University of Iowa and approximately 150 nationwide.

Start Date
June 26, 2013
End Date
June 1, 2015
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Daniel Vaena, MD
Contact Info

Clarine Halvorsen, 319-356-3944

cabozantinib ; cancer ; IRB#201305785 ; metastic kidney ; phase 2 ; phase II ; subitinib ; vaena ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.